Administering ziconotide and monitoring patients treated with ziconotide: Expert opinions

Pain Management Nursing

Volumn 14, Issue 3, 2013, Pages

  Mitchell, Alisia A ^a   Sapienza Crawford, Anne J ^b   Hanley, Kari L ^c   Lokey, Kristi J ^d   Wells, Linda ^e   McDowell, Gladstone C ^a   Stanton Hicks, Michael ^b  

^a Integrated Pain Solutions   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c Pain Care Associates   (United States)

^d Sparks Regional Medical Center/RC Goodman Pain Institute ^*  (United States)

^e South Pointe Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; OMEGA CONOTOXIN; OMEGA CONOTOXIN MVIIA;

ANALGESIA; CHRONIC PAIN; DRUG MONITORING; HUMAN; INTRASPINAL DRUG ADMINISTRATION; METHODOLOGY; REVIEW;

ANALGESICS, NON-NARCOTIC; CHRONIC PAIN; DRUG MONITORING; HUMANS; INJECTIONS, SPINAL; OMEGA-CONOTOXINS; PAIN MANAGEMENT;

EID: 84882704717     PISSN: 15249042     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pmn.2011.05.004     Document Type: Review

References (47)

1. Ballantyne J.C., Mao J. Opioid therapy for chronic pain. New England Journal of Medicine 2003, 349:1943-1953.
2. Bowersox S.S., Luther R. Pharmacotherapeutic potential of omega-conotoxin MVIIA (SNX-111), an N-type neuronal calcium channel blocker found in the venom of Conus magus. Toxicon 1998, 36:1651-1658.
3. Collins S.L., Moore R.A., McQuay H.J. The visual analogue pain intensity scale: What is moderate pain in millimetres?. Pain 1997, 72:95-97.
4. Concar D. Doctor snail. New Scientist 1996, 152:26-28.
5. Deer T., Krames E.S., Hassenbusch S.J., Burton A., Caraway D., Dupen S., Eisenach J., Erdek M., Grigsby E., Kim P., Levy R., McDowell G., Mekhail N., Panchal S., Prager J., Rauck R., Saulino M., Sitzman T., Staats P., Stanton-Hicks M., Stearns L., Willis K.D., Witt W., Follett K., Huntoon M., Liem L., Rathmell J., Wallace M., Buchser E., Cousins M., ver Donck A. Polyanalgesic Consensus Conference 2007: Recommendations for the management of pain by intrathecal (intraspinal) drug delivery: Report of an interdisciplinary expert panel. Neuromodulation 2007, 10:300-328.
6. Dooley D.J., Taylor C.P., Donevan S., Feltner D. Ca2+ channel alpha2delta ligands: Novel modulators of neurotransmission. Trends in Pharmacological Sciences 2007, 28:75-82.
7. Eisai (2009). Prialt: Summary of product characteristics. European Medicines Agency.
8. Elan Pharmaceuticals (2008). Prialt (ziconotide intrathecal infusion). South San Francisco, CA.
9. Ellis D.J., Dissanayake S., McGuire D., Charapata S.G., Staats P.S., Wallace M.S., Grove G.W., Vercruysse P. Continuous intrathecal infusion of ziconotide for treatment of chronic malignant and nonmalignant pain over 12 months: A prospective, open-label study. Neuromodulation 2008, 11:40-49.
10. Fletcher, Ronald (August 26, 2010). (Personal Communication). Azur Pharmaceuticals.
11. Fisher R., Hassenbusch S., Krames E., Leong M., Minehart M., Prager J., Staats P., Webster L., Willis D. A consensus statement regarding the present suggested titration for Prialt (ziconotide). Neuromodulation 2005, 8:153-154.
12. Gibbs W.W. A new way to spell relief: v-e-n-o-m. Atoxin from killer sea snails promises a better painkiller. Scientific American 1996, 274. 28, 30.
13. Gossop M. Clonidine and the treatment of the opiate withdrawal syndrome. Drug and Alcohol Dependence 1988, 21:253-259.
14. Gureje O., Von Korff M., Simon G.E., Gater R. Persistent pain and well-being: A World Health Organization study in primary care. Journal of the American Medical Association 1998, 280:147-151.
15. Harkins S.W., Price D.D., Braith J. Effects of extraversion and neuroticism on experimental pain, clinical pain, and illness behavior. Pain 1989, 36:209-218.
16. Hassenbusch S.J., Portenoy R.K., Cousins M., Buchser E., Deer T.R., du Pen S.L., Eisenach J., Follett K.A., Hildebrand K.R., Krames E.S., Levy R.M., Palmer P.P., Rathmell J.P., Rauck R.L., Staats P.S., Stearns L., Willis K.D. Polyanalgesic Consensus Conference 2003: An update on the management of pain by intraspinal drug delivery-Report of an expert panel. Journal of Pain and Symptom Management 2004, 27:540-563.
17. Hauser L., Anupindi R., Moore W. Hydroxyzine for the treatment of acute opioid withdrawal: A 20-year clinical experience. Resident and Staff Physician 2006, 52:24-32.
18. Krames E. Implantable devices for pain control: Spinal cord stimulation and intrathecal therapies. Best Practice & Research. Clinical Anaesthesiology 2002, 16:619-649.
19. Krames E., Chapple I. Reliability and clinical utility of an implanted intraSpinal catheter used in the treatment of spasticity and pain. Neuromodulation 2000, 3:7-14. 8703 W Catheter Study Group.
20. Kumar K., Kelly M., Pirlot T. Continuous intrathecal morphine treatment for chronic pain of nonmalignant etiology: Long-term benefits and efficacy. Surgical Neurology 2001, 55:79-86. discussion 86-78.
21. Li L., Liu X., Herr K. Postoperative pain intensity assessment: A comparison of four scales in Chinese adults. Pain Medicine 2007, 8:223-234.
22. Maier C., Gockel H.H., Gruhn K., Krumova E.K., Edel M.A. Increased risk of suicide under intrathecal ziconotide treatment?-A warning. Pain 2010.
23. Malmberg A.B., Yaksh T.L. Effect of continuous intrathecal infusion of omega-conopeptides, N-type calcium-channel blockers, on behavior and antinociception in the formalin and hot-plate tests in rats. Pain 1995, 60:83-90.
24. Medtronic (2002). Lioresal [package insert]. Minneapolis, MN.
25. Mitchell, A.A., Sapienza-Crawford, A.J., Hanley, K.L., Lokey, K.J., Wells, L. II, G.C.M., & Stanton-Hicks, M. (2010). Principles and techniques for weaning intrathecal opioids [poster]. In 14th Annual Meeting of the North American Neuromodulation Society (NANS). Las Vegas, NV.
26. Pasternak R.C., Smith S.C., Bairey-Merz C.N., Grundy S.M., Cleeman J.I., Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Journal of the American College of Cardiology 2002, 40:567-572.
27. Price D.D., McGrath P.A., Rafii A., Buckingham B. The validation of visual analogue scales as ratio scale measures for chronic and experimental pain. Pain 1983, 17:45-56.
28. Rauck R.L., Wallace M.S., Leong M.S., Minehart M., Webster L.R., Charapata S.G., Abraham J.E., Buffington D.E., Ellis D., Kartzinel R. A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. Journal of Pain and Symptom Management 2006, 31:393-406.
29. Rosenblum S., Fisher R., Caraway D., Saulino M. A clinical guide to weaning off intrathecal opioids. Practical Pain Management 2007, 7:43-46.
30. Ruan X. Drug-related side effects of long-term intrathecal morphine therapy. Pain Physician 2007, 10:357-366.
31. Shields D., Aclan A., Szatkowski A. Chemical stability of admixtures combining ziconotide with fentanyl or sufentanil during simulated intrathecal administration. International Journal of Pharmaceutical Compounding 2008, 12:463-466.
32. Shields D., Aclan A., Szatkowski A. Chemical stability of admixtures containing ziconotide 25 μg/ml and morphine sulfate 10 mg/ml or 20 mg/ml during simulated intrathecal administration. International Journal of Pharmaceutical Compounding 2008, 12:553-557.
33. Shields D., Montenegro R. Chemical stability of ziconotide-clonidine hydrochloride admixtures with and without morphine sulfate during simuated intrathecal administration. Neuromodulation 2007, 10:6-11.
34. Shields D., Montenegro R., Aclan J. Chemical stability of admixtures combining ziconotide with baclofen during simulated intrathecal administration. Neuromodulation 2007, 10:12-17.
35. Shields D., Montenegro R., Aclan J. Chemical stability of an admixture combining ziconotide and bupivacaine during simulated intrathecal administration. Neuromodulation 2007, 10:1-5.
36. Shields D., Montenegro R., Ragusa M. Chemical stability of admixtures combining ziconotide with morphine or hydromorphone during simulated intrathecal administration. Neuromodulation 2005, 8:257-263.
37. Singla A., Stojanovic M.P., Chen L., Mao J. Adifferential diagnosis of hyperalgesia, toxicity, and withdrawal from intrathecal morphine infusion. Anesthesia and Analgesia 2007, 105:1816-1819. table of contents.
38. Staats P.S., Yearwood T., Charapata S.G., Presley R.W., Wallace M.S., Byas-Smith M., Fisher R., Bryce D.A., Mangieri E.A., Luther R.R., Mayo M., McGuire D., Ellis D. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: A randomized controlled trial. JAMA 2004, 291:63-70.
39. Wilderness Emergency Medical Services Institute. (n.d.) Mankoski Pain Scale. Available at: Accessed June 24, 2011. http://www.wemsi.org/painscale.html.
40. Tait R.C., Chibnall J.T., Krause S. The Pain Disability Index: Psychometric properties. Pain 1990, 40:171-182.
41. Thompson J.C., Dunbar E., Laye R.R. Treatment challenges and complications with ziconotide monotherapy in established pump patients. Pain Physician 2006, 9:147-152.
42. Ver Donck A., Collins R., Rauck R.L., Nitescu P. An open-label, multicenter study of the safety and efficacy of intrathecal ziconotide for severe chronic pain when delivered via an external pump. Neuromodulation 2008, 11:103-111.
43. Wade J.B., Price D.D., Hamer R.M., Schwartz S.M., Hart R.P. An emotional component analysis of chronic pain. Pain 1990, 40:303-310.
44. Wallace M.S., Charapata S.G., Fisher R., Byas-Smith M., Staats P.S., Mayo M., McGuire D., Ellis D. Intrathecal ziconotide in the treatment of chronic nonmalignant pain: A randomized, double-blind, placebo-controlled clinical trial. Neuromodulation 2006, 9:75-86.
45. Washington State Agency Medical Directors' Group (2010). Interagency guideline on opioid dosing for chronic noncancer pain-2010 Update. Olympia, WA.
46. Webster L.R., Fakata K.L. Ziconotide for chronic severe pain. Practical Pain Management 2005, 5:47-56.
47. Winkelmüller W., Burchiel K., Buyten J.-P. Intrathecal opioid therapy for pain: Efficacy and outcomes. Neuromodulation 1999, 2:67-76.